Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 13/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1735083 | 1.00 | HSD11B1 (0.53) | HSD11B1HRH3RBP4CA12CA1 | |
| SCHEMBL1734455 | 0.88 | HSD11B1 (0.52) | HSD11B1RBP4TRPV1 | |
| SCHEMBL1734453 | 0.88 | HSD11B1 (0.52) | HSD11B1RBP4TRPV1 | |
| SCHEMBL1734703 | 0.88 | HSD11B1 (0.52) | HSD11B1RBP4TRPV1 | |
| SCHEMBL1735631 | 0.85 | HDAC2 (0.47) | HSD11B1CA12CA1CA2CA9 | |
| SCHEMBL1735718 | 0.85 | HSD11B1 (0.50) | HSD11B1RBP4GAATRPV1 | |
| SCHEMBL1735716 | 0.85 | HSD11B1 (0.50) | HSD11B1RBP4GAATRPV1 | |
| SCHEMBL1734700 | 0.84 | ALDH1A1 (0.51) | GAA | |
| SCHEMBL1734702 | 0.84 | ALDH1A1 (0.51) | GAA | |
| SCHEMBL1735665 | 0.84 | LMNA (0.48) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101641348-B | Imidazolidinone derivatives | HOFFMANN LA ROCHE | 2014-09-10 | — | — | CN | claimed |
| EP-2142533-B1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | claimed |
| WO-2011069003-A3 | METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-27 | — | — | WO | claimed |
| CN-101641348-A | Imidazolidinone derivatives | HOFFMANN LA ROCHE CH | 2010-02-03 | — | — | CN | claimed |
| EP-2142533-A1 | IMIDAZOLIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | claimed |
| US-7625902-B2 | Imidazolidinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | claimed |
| WO-2008119657-A1 | IMIDAZOLIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | claimed |
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-02 | — | — | US | claimed |
| CN-101641348-B | Imidazolidinone derivatives | HOFFMANN LA ROCHE | 2014-09-10 | — | — | CN | disclosed |
| EP-2142533-B1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011069003-A3 | METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-27 | — | — | WO | disclosed |
| CN-101641348-A | Imidazolidinone derivatives | HOFFMANN LA ROCHE CH | 2010-02-03 | — | — | CN | disclosed |
| EP-2142533-A1 | IMIDAZOLIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-7625902-B2 | Imidazolidinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008119657-A1 | IMIDAZOLIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | NR1H2, NR1H3, NR1I2 | HSD11B1 35/4885HRH3 577/4885RBP4 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.